Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MITO27: Pembrolizumab + Chemotherapy in Recurrent Ovarian Cancer
NCT03539328Phase 2Unknown
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Jun 2018
- Primary completion
- Apr 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Status: unknown.
02
Drugs
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT03539328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03539328.